Staley Capital Advisers Inc. Purchases 29,355 Shares of Pfizer Inc. (NYSE:PFE)

Key Points

• Staley Capital Advisers Inc. raised its stake in Pfizer Inc. by 1.4% during the first quarter, owning 2,179,773 shares valued at approximately $55.24 million.
• Analysts have issued mixed ratings on Pfizer, with a consensus rating of "Hold" and a target price averaging $28.12 per share.
• Pfizer recently announced a quarterly dividend of $0.43 per share, reflecting a 7.0% dividend yield and a payout ratio of 91.49%.

Staley Capital Advisers Inc. boosted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 1.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,179,773 shares of the biopharmaceutical company's stock after buying an additional 29,355 shares during the period. Pfizer makes up 2.5% of Staley Capital Advisers Inc.'s holdings, making the stock its 13th biggest holding. Staley Capital Advisers Inc.'s holdings in Pfizer were worth $55,235,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Brighton Jones LLC grew its position in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC lifted its stake in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after purchasing an additional 2,087 shares in the last quarter. Rockefeller Capital Management L.P. increased its holdings in shares of Pfizer by 2.2% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,665,404 shares of the biopharmaceutical company's stock worth $44,189,000 after buying an additional 35,315 shares during the last quarter. Sagespring Wealth Partners LLC bought a new position in shares of Pfizer in the 4th quarter worth $1,117,000. Finally, WealthTrust Axiom LLC grew its holdings in shares of Pfizer by 10.7% during the 4th quarter. WealthTrust Axiom LLC now owns 197,648 shares of the biopharmaceutical company's stock valued at $5,244,000 after purchasing an additional 19,035 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

NYSE PFE traded up $0.49 during trading hours on Wednesday, hitting $25.14. 40,139,280 shares of the company's stock traded hands, compared to its average volume of 45,842,215. The firm has a market capitalization of $142.93 billion, a P/E ratio of 13.37, a P/E/G ratio of 0.88 and a beta of 0.52. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The business's fifty day moving average price is $24.49 and its two-hundred day moving average price is $24.47. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.60 earnings per share. Equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. Pfizer's dividend payout ratio is presently 91.49%.

Analysts Set New Price Targets

Several equities research analysts have weighed in on PFE shares. BMO Capital Markets dropped their price target on shares of Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. HSBC dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Redburn Atlantic decreased their target price on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research note on Wednesday, April 30th. Cantor Fitzgerald began coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. Finally, Wolfe Research lifted their target price on shares of Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.